Product References — Single Donor Human Complement Serum

Top 5 Biologicals to Buy Right Now

Posted by Adam Awdish on

Top 5 Biologicals to Buy Right Now

Innovative Research is excited to share our top 5 biological products that are making waves in the scientific community right now. These products are designed to support your research and provide reliable, high-quality results. Cerebrospinal Fluid (CSF) Our Pooled Human Cerebrospinal Fluid (CSF) is an essential resource in neurology and neuroscience research and one of our current most popular products. Our CSF products are sourced as medical remnants and can be used for a variety of applications. Complement Serum Complement Serum is a vital component of the immune system and plays a crucial role in the body’s defense against infections. Taken from...

Read more →

Cytoprotective IgG Antibodies in Sera from a Subset of Patients with AQP4‑IgG Seropositive Neuromyelitis Optica Spectrum Disorder

Posted by Adam Awdish on

Cytoprotective IgG Antibodies in Sera from a Subset of Patients with AQP4‑IgG Seropositive Neuromyelitis Optica Spectrum Disorder

Single Donor Human Complement Serum from Innovative Research was used in the following study:   Cytoprotective IgG Antibodies in Sera from a Subset of Patients with AQP4‑IgG Seropositive Neuromyelitis Optica Spectrum Disorder LukmaneeTradtrantip, Michael R. Yeaman & A. S. Verkman Scientific Reports November 9, 2021 Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disorder that attacks the central nervous system and can cause demyelination in the optic nerve, spinal cord, and brain, and potentially cause further neurological deficits. Over 70% of patients suffering from NMOSD are seropositive for IgG autoantibodies which target extracellular epitopes of astrocyte water channel aquaporin-4 (AQP4),...

Read more →

Development of a Sensitive Assay to Screen Nanoparticles in vitro for Complement Activation

Posted by Adam Awdish on

Development of a Sensitive Assay to Screen Nanoparticles in vitro for Complement Activation

Single Donor Human Whole Blood, Single Donor Human Plasma (Blood Derived), Single Donor Human Complement Serum, Innovative Grade US Origin Porcine Plasma, and Innovative Grade US Origin Porcine Whole Blood from Innovative Research were used in the following study:   Development of a Sensitive Assay to Screen Nanoparticles in vitro for Complement Activation Nuzhat Maisha, Tobias Coombs, and Erin B. Lavik American Chemical Society July 6, 2020 Nanomedicines are often recognized by the innate immune system as a threat, leading to unwanted clearance due to complement activation. This unwanted reaction not only alters the bioavailability of the therapeutic, but can...

Read more →

Human CTLA4-Ig therapy can give false-positive anti-pig antibody results in primates after xenotransplantation

Posted by Corey Marcath on

Human CTLA4-Ig therapy can give false-positive anti-pig antibody results in primates after xenotransplantation

Single Donor Human Complement Serum from Innovative Research was used in the following study:   Human CTLA4-Ig therapy can give false-positive anti-pig antibody results in primates after xenotransplantation Qi Li, Takayuki Yamamoto, Hayato Iwase, Huy Quoc Nguyen, Yi Wang, David Ayares, David K.C.Cooper, Hidetaka Hara Transplant Immunology December 2019 “…Background: Measurement of serum anti-pig antibodies is an important parameter in immune monitoring after pig-to-nonhuman primate xenotransplantation. Pig aortic endothelial cells (pAECs) are commonly used for this purpose. However, human (h) CTLA4-Ig (abatacept/belatacept) could bind to pCD80/86 on the cells, and a secondary antibody (i.e., anti-human IgG) may recognize hCTLA4-Ig (in...

Read more →

CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica

Posted by Leanne Kodsmann on

CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica

Human Complement from Innovative Research was used in the following study:   CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica Lukmanee Tradtrantip, Tianjiao Duan, Michael R. Yeaman, Alan S. Verkman Journal of Neuroinflammation December 2019, 16:57 "... Neuromyelitis optica spectrum disorder (herein called NMO) is an inflammatory demyelinating disease that can be initiated by binding of immunoglobulin G autoantibodies (AQP4-IgG) to aquaporin-4 on astrocytes, causing complement-dependent cytotoxicity (CDC) and downstream inflammation. The increased NMO pathology in rodents deficient in complement regulator protein CD59 following passive transfer of AQP4-IgG has suggested the potential therapeutic utility...

Read more →


×